Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | USP5 | P45974 | 2/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.38 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | QDPR | P09417 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29389392 | 1.00 | HTR2A (0.46) | HTR2AHTR2CHTR2BKDM1AMAOB | |
| Ammonia Solution, Strong SCHEMBL2142374 | 0.98 | HTR2A (0.44) | HTR2AHTR2CHTR2BKDM1AMAOB | |
| Hydrochloric Acid SCHEMBL27914628 | 0.95 | HTR2A (0.47) | HTR2AHTR2CHTR2BKDM1AMAOB | |
| Methyl Alcohol SCHEMBL27955336 | 0.93 | HTR2A (0.42) | HTR2AHTR2CHTR2BKDM1AMAOB | |
| SCHEMBL17827776 | 0.93 | HTR2A (0.42) | HTR2AHTR2CHTR2BKDM1AMAOB | |
| SCHEMBL18503358 | 0.91 | HTR2A (0.41) | HTR2AHTR2CHTR2BKDM1AMAOB | |
| SCHEMBL12917832 | 0.91 | GRIA4 (0.43) | HTR2AHTR2CHTR2BKDM1AMAOB | |
| SCHEMBL7762634 | 0.89 | HTR2A (0.40) | HTR2AHTR2CHTR2BKDM1AMAOB | |
| SCHEMBL21228907 | 0.89 | HTR2A (0.40) | HTR2AHTR2CHTR2BKDM1AMAOB | |
| SCHEMBL9979948 | 0.89 | ESR2 (0.52) | HTR2AHTR2CHTR2BKDM1AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106631887-A | Preparation process for (1R,2S)-1-cyano-2-(3,4-difluoro-phenyl)cyclopropane | 青岛云天生物技术有限公司 | 2017-05-10 | — | — | CN | claimed |
| EP-3955929-A1 | NEW PYRIMIDINE DERIVATIVES FOR PREVENTION AND TREATMENT OF GRAM-NEGATIVE BACTERIAL INFECTION, CONTAMINATION AND FOULING | Université de Liège (BE) | 2022-02-23 | — | — | EP | disclosed |
| EP-3919497-A1 | PROCESS FOR THE PREPARATION OF TICAGRELOR | Zaklady Farmaceutyczne Polpharma S.A. (PL) | 2021-12-08 | — | — | EP | disclosed |
| EP-3736265-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | Oryzon Genomics, S.A. (ES) | 2020-11-11 | — | — | EP | disclosed |
| WO-2020212553-A1 | NEW PYRIMIDINE DERIVATIVES FOR PREVENTION AND TREATMENT OF GRAM-NEGATIVE BACTERIAL INFECTION, CONTAMINATION AND FOULING | Université de Liège (BE) | 2020-10-22 | — | — | WO | disclosed |
| EP-2768805-B1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS SA (ES) | 2020-03-25 | — | — | EP | disclosed |
| EP-2755957-B2 | SYNTHESIS OF TRIAZOLOPYRIMIDINE COMPOUNDS | LEK PHARMACEUTICALS (SI) | 2019-05-15 | — | — | EP | disclosed |
| US-20180148745-A1 | HEMOPROTEIN CATALYSTS FOR IMPROVED ENANTIOSELECTIVE ENZYMATIC SYNTHESIS OF TICAGRELOR | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2018-05-31 | — | — | US | disclosed |
| US-9982061-B2 | Antibodies to ticagrelor and methods of use | MEDIMMUNE LIMITED (GB) | 2018-05-29 | — | — | US | disclosed |
| CN-106565503-B | The method for synthesizing (1R, 2S) -1- amino-(3,4- difluorophenyls)-cyclopropane | 华北理工大学 | 2018-04-24 | — | — | CN | disclosed |
| WO-2013037942-A1 | SYNTHESIS OF TRIAZOLOPYRIMIDINE COMPOUNDS | LEK PHARMACEUTICALS D.D. (SI) | 2013-03-21 | — | — | WO | disclosed |
| EP-2570405-A1 | Synthesis of Triazolopyrimidine Compounds | LEK Pharmaceuticals d.d. (SI) | 2013-03-20 | — | — | EP | disclosed |
| WO-2013023511-A1 | TRIAZOLOPYRIMIDINE DERIVATIVE AND PREPARATION METHOD AND USE THEREOF | 上海恒瑞医药有限公司 (CN) | 2013-02-21 | — | — | WO | disclosed |
| WO-2012138981-A2 | NEW INTERMEDIATES AND PROCESSES FOR PREPARING TICAGRELOR | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2012-10-11 | — | — | WO | disclosed |
| EP-2292582-A3 | 2-substituted 1-(3,4-difluorophenyl)cyclopropane derivatives | AstraZeneca AB (SE) | 2011-11-02 | — | — | EP | disclosed |
| US-20110137056-A1 | Chemical Process For Preparation Of Intermediates | ASTRAZENECA AB (SE) | 2011-06-09 | — | — | US | disclosed |
| EP-2292582-A2 | 2-substituted 1-(3,4-difluorophenyl)cyclopropane derivatives | AstraZeneca AB (SE) | 2011-03-09 | — | — | EP | disclosed |
| WO-2011017108-A2 | CYCLOPROPYL MODULATORS OF P2Y12 RECEPTOR | AUSPEX PHARMACEUTICALS, INC. (US) | 2011-02-10 | — | — | WO | disclosed |
| US-7863469-B2 | preparing the enantiomerically pure carboxylic acid derivatives ethyl (1R,2R)-trans2-(3,4-difluorophenyl)cyclopropyl carboxylate; as starting material for trans2-(3,4-difluorophenyl)cyclopropyl carboxamide; chemical intermediates for producing platelet receptor antagonists, anticoagulants | ASTRAZENECA AB (SE) | 2011-01-04 | — | — | US | disclosed |
| US-20080132719-A1 | preparing the enantiomerically pure carboxylic acid derivatives ethyl (1R,2R)-trans2-(3,4-difluorophenyl)cyclopropyl carboxylate; as starting material for trans2-(3,4-difluorophenyl)cyclopropyl carboxamide; chemical intermediates for producing platelet receptor antagonists, anticoagulants | ASTRAZENECA AB (SE) | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110137056-A1 | Chemical Process For Preparation Of Intermediates | DHPS, CYP3A5, CYP3A43 | HTR2A 3056/4885HTR2C 2268/4885HTR2B 3200/4885 |
| US-20080132719-A1 | preparing the enantiomerically pure carboxylic acid derivatives ethyl (1R,2R)-trans2-(3,4-difluorophenyl)cyclopropyl carboxylate; as starting material for trans2-(3,4-difluorophenyl)cyclopropyl carboxamide; chemical intermediates for producing platelet receptor antagonists, anticoagulants | TBXA2R, F2R, F2 | HTR2A 372/4885HTR2C 474/4885HTR2B 789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.